Cantor Fitzgerald Initiates Coverage On Sensei Biotherapeutics with Overweight Rating

Benzinga Newsdesk www.benzinga.com Positive 61.0%

Neg 0% Neu 0% Pos 61%

Cantor Fitzgerald analyst Li Watsek initiates coverage on Sensei Biotherapeutics (NASDAQ:SNSE) with a Overweight rating.